Maravai LifeSciences Holdings, Inc. (MRVI) Stock Analysis
A live, multi-source view of Maravai LifeSciences Holdings, Inc. (MRVI): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services.
Sector: Healthcare · Industry: Biotechnology · United States · 415 employees · maravai.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Maravai LifeSciences Holdings, Inc. (MRVI) had a market capitalization of $2.71B (forward -72.9) and a beta of 0.60; the shares traded in a 52-week range of $2.42 – $9.42 (200.0% over the year).
- Market cap
- $2.71B
- Enterprise value
- $1.39B
- Forward P/E
- -72.9
- Price / book
- 5.33
- EPS (trailing)
- $-0.53
- EPS (forward)
- $-0.10
- Payout ratio
- 0.0%
- 52-week range
- $2.42 – $9.42
- 52-week change
- 200.0%
- Beta
- 0.60
- Average volume
- 3.5M
- Shares outstanding
- 149.0M
- Short % of float
- 7.46%
- Profit margin
- -37.1%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Maravai LifeSciences Holdings, Inc. (MRVI) last closed at $6.73 (the last completed close before that scan).
Technicals at the scan: RSI 43 (neutral territory), price -8.7% versus its 20-day average, 20-day versus 50-day average spread +8.1%, MACD histogram -0.16.
Sentiment inputs: StockTwits 67% bullish; analyst consensus score 64/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for MRVI in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
MRVI has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Maravai LifeSciences Holdings, Inc. (MRVI) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell MRVI.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.